Early Changes in Auditory Function As a Result of Platinum Chemotherapy: Use of Extended High-Frequency Audiometry and Evoked Distortion Product Otoacoustic Emissions

2007 ◽  
Vol 25 (10) ◽  
pp. 1190-1195 ◽  
Author(s):  
Kristin R. Knight ◽  
Dale F. Kraemer ◽  
Christiane Winter ◽  
Edward A. Neuwelt
Keyword(s):  
High Frequency ◽  
Otoacoustic Emissions ◽  
Distortion Product Otoacoustic Emissions ◽  
Auditory Function ◽  
Cochlear Function ◽  
Serial Measurement ◽  
Distortion Product ◽  
High Frequency Audiometry ◽  
Platinum Based Chemotherapy ◽  
Platinum Chemotherapy

Purpose The objective is to describe progressive changes in hearing and cochlear function in children and adolescents treated with platinum-based chemotherapy and to begin preliminary evaluation of the feasibility of extended high-frequency audiometry and distortion product otoacoustic emissions for ototoxicity monitoring in children. Patients and Methods Baseline and serial measurement of conventional pure-tone audiometry (0.5 to 8 kHz) and evoked distortion product otoacoustic emissions (DPOAEs) were conducted for 32 patients age 8 months to 20 years who were treated with cisplatin and/or carboplatin chemotherapy. Seventeen children also had baseline and serial measurement of extended high-frequency (EHF) audiometry (9 to 16 kHz). Audiologic data were analyzed to determine the incidence of ototoxicity using the American Speech-Language-Hearing Association criteria, and the relationships between the different measures of ototoxicity. Results Of the 32 children, 20 (62.5%) acquired bilateral ototoxicity in the conventional frequency range during chemotherapy treatment, and 26 (81.3%) had bilateral decreases in DPOAE amplitudes and dynamic range. Of the 17 children with EHF audiometry results, 16 (94.1%) had bilateral ototoxicity in the EHF range. Pilot data suggest that EHF thresholds and DPOAEs show ototoxic changes before hearing loss is detected by conventional audiometry. Conclusion EHF audiometry and DPOAEs have the potential to reveal earlier changes in auditory function than conventional frequency audiometry during platinum chemotherapy in children.

scholarly journals Does Vincristine affect Cochlear function in children with acute lymphoblastic leukaemia?

2016 ◽  
Vol 27 (1) ◽  
pp. 3-7
Author(s):  
Suchetha Rao ◽  
Ranjith Kumar ◽  
Jayashree Bhat ◽  
Nutan Kamath
Keyword(s):  
High Frequency ◽  
Otoacoustic Emissions ◽  
Lymphoblastic Leukemia ◽  
Statistical Significance ◽  
Pure Tone Audiometry ◽  
Cochlear Function ◽  
Hearing Sensitivity ◽  
Distortion Product ◽  
High Frequency Audiometry

Context: Vincristine chemotherapy has dose dependent ototoxicity. Early detection of ototoxicity is better with otoacoustic emissions and high frequency audiometry than conventional pure tone audiometry. The study was done to see if vincristine treatment interferes with hearing sensitivity in children.Methods and Material: A prospective study was conducted on twenty-three children with acute lymphoblastic leukemia (ALL) on Multi Center Protocol (MCP 841).These were subjected to conventional audiometry, high frequency audiometry and distortion product otoacoustic emissions (DPOAEs) before starting chemotherapy. The follow up audiological evaluation after early intensive phase chemotherapy (approximately 6 months) was conducted in thirteen children, who received 12 doses of vincristine (1.4 mg/m2), cranial irradiation of 1800cGy (>3 years) as per protocol and antibiotics as per clinical demands.Results: Baseline audiological evaluation was normal. Follow-up evaluation DPOAEs showed a declining tendency, however changes did not reach statistical significance. Differences in median hearing thresholds prior and post treatment in higher frequency audiometry were also minimal which was not statistically significant. Conventional audiometric thresholds were not altered.Conclusions: The reduction in the signal noise ratio of DPOAE, and reduced hearing sensitivity in high frequencies in post chemotherapy in comparison with baseline measures cannot be ignored though it has failed to reach the level of statistical significance. children on vincristine should have a pre chemotherapy and follow up audiological evaluation with DPOAE The results of the present study needs to be strengthened by including larger sample and long term follow up.Bangladesh J Medicine Jan 2016; 27(1) : 3-7

scholarly journals Acquisition and Repeatability of High-Frequency Distortion Product Otoacoustic Emissions Using Two Different Calibration Methods in Newborns

2019 ◽  
Vol 9 (15) ◽  
pp. 2947
Author(s):  
Laura Dreisbach Hawe ◽  
Nicholas Portugal ◽  
Eliza Aguilar ◽  
William Hansen ◽  
Daniela Kite ◽  
...  
Keyword(s):  
High Frequency ◽  
Otoacoustic Emissions ◽  
Pressure Level ◽  
Distortion Product Otoacoustic Emissions ◽  
Cochlear Function ◽  
Distortion Product ◽  
Calibration Methods ◽  
Stimulus Parameters ◽  
Adults And Children ◽  
Objective Tests

Distortion-product otoacoustic emissions (DPOAEs) elicited with high-frequency (HF; up to 16 kHz) stimuli are measurable and repeatable in normal-hearing adults and children, adult patients, and are sensitive to ototoxic insults in adults. However, objective tests for monitoring basal cochlear function in those too young to respond subjectively need to be developed. DPOAE levels recorded at frequencies <10 kHz are well characterized, but DPOAE levels measured up to 16 kHz do not exist for newborns. The goal of the current study is to determine if HF DPOAEs are measurable and repeatable in newborns. DPOAEs were measured from 2–16 kHz (f2/f1 of 1.22; L1/L2 = 65/55 dB SPL) using two different calibration methods (forward pressure level—FPL and in-the-ear—SPL) in 26 newborns. To assess repeatability, the probe was removed then re-inserted for a second round of testing. Results indicate that HF DPOAEs can be evoked and are repeatable in newborns and the use of FPL calibration shows promise for measuring HF responses and maximizing repeatability. To be implemented in monitoring programs where the highest frequencies with responses are continuously tested, stimulus parameters used to evoke newborn HF DPOAEs and calibration methods need further exploration.

Evaluating cochlear function and the effects of noise exposure in the B6.CAST+Ahl mouse with distortion product otoacoustic emissions

2004 ◽  
Vol 194 (1-2) ◽  
pp. 87-96 ◽  
Author(s):  
Ana E Vázquez ◽  
Ana M Jimenez ◽  
Glen K Martin ◽  
Anne E Luebke ◽  
Brenda L Lonsbury-Martin
Keyword(s):  
Otoacoustic Emissions ◽  
Noise Exposure ◽  
Distortion Product Otoacoustic Emissions ◽  
Cochlear Function ◽  
Distortion Product

scholarly journals Relationship Between Distortion Product – Otoacoustic Emissions (DPOAEs) and High-Frequency Acoustic Immittance Measures

2016 ◽  
Vol 22 ◽  
pp. 2028-2034 ◽  
Author(s):  
Ualace De Paula Campos ◽  
Stavros Hatzopoulos ◽  
Lech K. Śliwa ◽  
Piotr H. Skarżyński ◽  
Wiesław W. Jędrzejczak ◽  
...  
Keyword(s):  
High Frequency ◽  
Otoacoustic Emissions ◽  
Distortion Product Otoacoustic Emissions ◽  
Distortion Product

scholarly journals Time-domain analysis of distortion-product otoacoustic emissions using a hydrodynamic cochlea model

2017 ◽  
Vol 3 (2) ◽  
pp. 453-456
Author(s):  
Dennis Zelle ◽  
Ernst Dalhoff ◽  
Anthony W. Gummer
Keyword(s):  
Time Domain ◽  
Otoacoustic Emissions ◽  
Short Pulse ◽  
Human Subjects ◽  
Time Domain Analysis ◽  
Distortion Product Otoacoustic Emissions ◽  
Sound Waves ◽  
Cochlear Function ◽  
Distortion Product ◽  
The Time Domain

AbstractAs a by-product of nonlinear amplification in the cochlea, the inner ear emits sound waves in response to two tones with different frequencies. These sound waves are measurable in the ear canal as distortion-product otoacoustic emissions (DPOAEs). DPOAEs putatively consist of two components emerging at different locations in the cochlea. Wave interference between the two components limits the accuracy of DPOAEs as a noninvasive measure of cochlear function. Using short stimulus pulses instead of continuous stimuli, the two DPOAE components can be separated in the time domain due to their different latencies. The present work utilizes a nonlinear hydrodynamic cochlea model to simulate short-pulse DPOAEs in the time domain. When adding irregularities to the mechanical parameters of the model, the simulated DPOAE signals show two distinguishable components and long-lasting beat tones, similar to band-pass filtered experimental data from normal-hearing human subjects. The model results suggest that the beat tones can occur solely due to interference of the coherent-reflection component with the fading nonlinear-distortion component.

Effects of Oxaliplatin, Carboplatin, and Cisplatin Across Treatment on High-Frequency Objective and Subjective Auditory Measures in Adults

2017 ◽  
Vol 2 (6) ◽  
pp. 17-38 ◽  
Author(s):  
Laura Dreisbach ◽  
Melissa Ho ◽  
Erin Reid ◽  
Jonathan Siegel
Keyword(s):  
High Frequency ◽  
Otoacoustic Emission ◽  
Distortion Product Otoacoustic Emission ◽  
Chemotherapy Treatment ◽  
Auditory Function ◽  
Distortion Product ◽  
Behavioral Thresholds ◽  
Group Data ◽  
Platinum Chemotherapy ◽  
Early Damage

Platinum chemotherapies are often ototoxic, initially affecting the basal end of the cochlea. Thus, monitoring high-frequency auditory function is advised to reveal early damage. Objective measures of high-frequency auditory function are repeatable over time, but the sensitivity of these measures for monitoring patients receiving platinum derivatives have not been established. We monitored 13 patients across oxaliplatin, carboplatin, or cisplatin treatment using the highest frequencies with responses for each individual. Behavioral thresholds and distortion product otoacoustic emission (DPOAE) gross frequency (f2=16–2 kHz) and concentrated frequency (1/48 octave steps at the highest frequency with a present DPOAE) sweeps were monitored. DPOAE results indicated changes during treatment within individuals using absolute change criteria, as well as statistically significant differences across trial when analyzing group data. Changes varied depending on the drug administered. Behavioral thresholds changed less often than DPOAE measures and when changes were noted, they initially occurred at the highest frequencies monitored. Often, DPOAE changes occurred at frequencies which conventional equipment could not monitor (>8 kHz). Additionally, some changes were characterized by DPOAE level enhancements at conventional frequencies (<8 kHz), while levels at higher frequencies were reduced. Overall, objective high-frequency measures were sensitive to auditory changes in adults undergoing platinum chemotherapy treatment.

Sign in / Sign up

Export Citation Format

Share Document